First Light Asset Management, LLC and Mathew P. Arens jointly filed Amendment No. 3 to a Schedule 13G with the SEC on November 16, 2026, disclosing beneficial ownership positions in Neogenomics, Inc. (NASDAQ:NEO) common stock as of September 30, 2026.

Key Highlights

  • Arens aggregate ownership: Mathew P. Arens beneficially owns 8,937,280 shares of Neogenomics common stock, representing 6.91% of the class.
  • Manager ownership: First Light Asset Management, LLC beneficially owns 8,437,880 shares, representing 6.52% of the class.
  • Direct personal holdings: Arens directly holds 235,000 shares in an individual capacity with sole voting and dispositive power, and 264,400 shares in a joint account with shared control.
  • Shared voting power: First Light Asset Management, LLC holds shared voting power over all 8,437,880 of its reported shares; sole voting power is zero.
  • Triggering event date: The date of event requiring this filing is September 30, 2026.
  • Filing basis: The amendment is filed pursuant to Rule 13d-1(b) under the Securities Exchange Act of 1934.

First Light and Arens Detail Neogenomics Holdings in Amended 13G

According to the filing, First Light Asset Management, LLC serves as an investment adviser to separately managed accounts and certain private funds that hold shares of Neogenomics, Inc. common stock (par value $0.01, CUSIP 64049M209). The Manager is deemed a beneficial owner of 8,437,880 shares because it acts in that advisory capacity. All 8,437,880 shares are held with shared voting and shared dispositive power; the Manager reports zero sole voting or sole dispositive power.

Mathew P. Arens, identified in the filing as the managing member and majority owner of First Light Asset Management, LLC, is deemed a beneficial owner of the same shares attributed to the Manager. In addition, Arens directly holds 235,000 shares with sole voting and sole dispositive power in an individual capacity, and 264,400 shares in a joint account over which he shares control. His total aggregate beneficial ownership reported is 8,937,280 shares, equal to 6.91% of the class. The filing notes that Arens also holds the title of Chief Executive Officer, as indicated by his signature block.

The filing states that it "shall not be construed as an admission that the reporting persons or any of their affiliates are the beneficial owner of any securities covered by this Schedule 13G for any other purposes other than Section 13(d) of the Securities Exchange Act of 1934." Both reporting persons certify that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer." The principal business address for both reporting persons is 3300 Edinborough Way, Suite 201, Edina, MN 55435.

What Was Disclosed

First Light Asset Management, LLC and Mathew P. Arens filed Amendment No. 3 to Schedule 13G reporting combined beneficial ownership of Neogenomics common stock, with Arens at 6.91% and the Manager at 6.52%, triggered by an event dated September 30, 2026.